Update in Lawsuit for Investors in NewLink Genetics Corp (NASDAQ: NLNK) Shares Announced by Shareholders Foundation

SAN DIEGO, CA / ACCESSWIRE / May 30, 2017 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain purchasers of NASDAQ: NLNK shares against NewLink Genetics Corp over alleged Violations of Securities Laws.

Investors who purchased shares of NewLink Genetics Corp (NASDAQ: NLNK) in August 2013 or earlier and continue to hold any of those NASDAQ: NLNK shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.

On May 09, 2016, NewLink Genetics Corp announced the results of its Phase 3 clinical trial for algenpantucel-L for patients with resected pancreatic cancer. NewLink Genetics Corp said that the IMPRESS Phase 3 study of algenpantucel-L for patients with resected pancreatic cancer did not achieve its primary endpoint.

On May 12, 2016, a lawsuit was filed against NewLink Genetics Corp over alleged securities laws violations. The plaintiff alleged that the defendants made false and/or misleading statements and/or failed to disclose thatthe Company’s algenpantucel-L treatment was ineffective and potentially harmful to patients, and that as a result of the foregoing, NewLink’s public statements were materially false and misleading at all relevant times. On October 31, 2016, respectively November 10, 2016, an amended complaint was filed.

Those who purchased NewLink Genetics Corp (NASDAQ: NLNK) shares should contact the Shareholders Foundation, Inc.

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

CONTACT:

Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108

SOURCE: Shareholders Foundation, Inc.

ReleaseID: 464395